Amarin
is an Ireland-based pharmaceutical company that researches and develops novel therapeutics for the treatment of cardiovascular diseases... Read moreAmarin
is an Ireland-based pharmaceutical company that researches and develops novel therapeutics for the treatment of cardiovascular diseases... Read more
News
Apr 30, 2026
Zacks
Amarin: Amarin's Q1 Loss Narrower Than Expected, Sales Increase Y/Y
Apr 29, 2026
Owler
Amarin Corporation plc: Amarin's revenue changed from $182.75M in Dec 2025 to $185.04M in Mar 2026
Apr 29, 2026
GlobeNewswire
Press Release: Amarin : Amarin Reports 2026 First Quarter Financial Results
Apr 29, 2026
Seeking Alpha
Amarin: Amarin GAAP EPS of -$0.03 misses by $0.04, revenue of $45.1M beats by $1.33M
Mar 18, 2026
GlobalNewswire
Press Release: Amarin : Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline
Mar 16, 2026
StreetInsider
Press Release: Amarin : New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the
Mar 06, 2026
Owler
Amarin Corporation plc: Amarin's employee count changed from 275 in Dec 2024 to 80 in Dec 2025
Mar 05, 2026
Zacks
Amarin: AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know
Mar 02, 2026
GlobalNewswire
Press Release: Amarin : Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT Post Hoc Analysis Published in the European Journal of Preventive Cardiology
Feb 26, 2026
Seeking Alpha
Amarin: Amarin Corporation plc 2025 Q4 - Results - Earnings Call Presentation
Amarin Competitors
1
2
3
4
5
6
7
8
9
10